NCCS Joins Cancer Leadership Council (CLC) in Comments to CMS Regarding “Protected Classes”
NCCS joined its colleagues in the Cancer Leadership Council in urging the Centers for Medicare & Medicaid Services (CMS) to reconsider the new policy on classes of clinical concern that has been proposed for Medicare Part D beginning in contract year 2015. CMS has proposed removing three classes of drugs from “protected classes” status. In […]